"versionIdentifier","rationale","id","uuid:ID","instanceType"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","491fc5ea-6d61-4852-af55-a5d1a00efb20","StudyVersion"
